- Home
- LYEL vs OABI Comparison
LYEL vs OABI Comparison
Compare LYEL & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- OABI
- Stock Information
- Founded
- LYEL 2018
- OABI 2012
- Country
- LYEL United States
- OABI United States
- Employees
- LYEL N/A
- OABI N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- LYEL Health Care
- OABI Health Care
- Exchange
- LYEL Nasdaq
- OABI Nasdaq
- Market Cap
- LYEL 253.2M
- OABI 239.0M
- IPO Year
- LYEL 2021
- OABI N/A
- Fundamental
- Price
- LYEL $15.95
- OABI $1.48
- Analyst Decision
- LYEL Hold
- OABI Strong Buy
- Analyst Count
- LYEL 3
- OABI 3
- Target Price
- LYEL $16.67
- OABI $6.67
- AVG Volume (30 Days)
- LYEL 27.0K
- OABI 528.2K
- Earning Date
- LYEL 11-12-2025
- OABI 11-04-2025
- Dividend Yield
- LYEL N/A
- OABI N/A
- EPS Growth
- LYEL N/A
- OABI N/A
- EPS
- LYEL N/A
- OABI N/A
- Revenue
- LYEL $60,000.00
- OABI $23,027,000.00
- Revenue This Year
- LYEL N/A
- OABI N/A
- Revenue Next Year
- LYEL N/A
- OABI $48.89
- P/E Ratio
- LYEL N/A
- OABI N/A
- Revenue Growth
- LYEL 11.11
- OABI 6.05
- 52 Week Low
- LYEL $7.65
- OABI $1.22
- 52 Week High
- LYEL $30.00
- OABI $4.87
- Technical
- Relative Strength Index (RSI)
- LYEL 47.03
- OABI 39.85
- Support Level
- LYEL $16.29
- OABI $1.45
- Resistance Level
- LYEL $18.60
- OABI $1.56
- Average True Range (ATR)
- LYEL 1.06
- OABI 0.09
- MACD
- LYEL -0.31
- OABI -0.02
- Stochastic Oscillator
- LYEL 6.36
- OABI 8.70
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.